October 7 2021

Vasopharm announces results of the post hoc analyses of the Traumatic Brain Injury Phase III Study (NOSTRA III)

Post hoc analyses of the NOSTRA III clinical phase III trial revealed clinically meaningful and statistically significant differences between placebo and verum group in favour of a beneficial action of the drug.

vasopharm GmbH, a privately-held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, today announces that the post hoc analyses of the NOSTRA III clinical phase III trial revealed clinically meaningful and statistically significant differences between placebo and verum group in favour of a beneficial action of the drug. This data is currently the basis for a new patent application and will be disclosed after its submission. Consequently, whilst the company is eager and willing to discuss this data with interested parties, the data can only be disclosed under NDA.

back